EVALUATION OF ENDOTOXIN MODELS FOR THE STUDY OF SEPSIS
- 1 December 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Shock
- Vol. 24 (Supplement) , 7-11
Abstract
Many strategies have been proposed for the treatment of sepsis, and most of the proposed treatment modalities have failed in clinical trials. Many of the previous treatment protocols called for blocking the activity of a single, clearly defined mediator. The underlying hypothesis was that sepsis induced a specific mediator that then caused organ injury and death. This simple, linear reasoning was frequently based on cytokines that were defined using endotoxin models of sepsis. The endotoxin models were widely used to study the pathophysiology of sepsis and were felt to adequately reproduce the full spectrum of inflammatory changes observed in patients with sepsis. Based on mortality and hematologic changes, these assumptions appeared justified. As the models were examined more closely, and directly compared with focus of infection models that more accurately portray the changes in sepsis, it became apparent that the endotoxin models did not accurately mimic the patient with sepsis. In the endotoxin models, the explosive release of cytokines into the circulating blood volume was reproducibly found regardless of the species studied (human, primate, pig, rat, or mouse). This lead to a series of anticytokine sepsis trials, all of which failed. The cytokine response in focus of infection models, such as that induced by cecal ligation and puncture, was examined and found to be more similar to that observed in patients with sepsis. When cytokine inhibitor strategies were used in the cecal ligation and puncture model, they were also generally found to lack efficacy. Compounds that have been shown to be effective at reducing mortality in endotoxin models should be re-evaluated in more clinically relevant models of sepsis.Keywords
This publication has 66 references indexed in Scilit:
- Clinical Equipoise Remains for Issues of Adrenocorticotropic Hormone Administration, Cortisol Testing, and Therapeutic Use of HydrocortisoneCritical Care Medicine, 2003
- Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failureCritical Care Medicine, 2003
- Dynamic regulation of the proinflammatory cytokine, interleukin-1β: Molecular biology for non-molecular biologistsLife Sciences, 1999
- Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trialCritical Care Medicine, 1994
- Dissociation between plasma and monocyte‐associated cytokines during sepsisEuropean Journal of Immunology, 1991
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.Journal of Experimental Medicine, 1988
- Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.Journal of Clinical Investigation, 1988
- ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASEThe Lancet, 1987
- Tumor necrosis factor-induced alterations in circulating leukocyte populationsBiochemical and Biophysical Research Communications, 1986